In prostate cancer, especially in the PTEN-null phenotype, upregulation of ARID4B activates the PTEN-PI3K pathway through specific transactivation of both PIK3CA and PIK3R2, which favors tumor progression and correlates positively with prostate cancer recurrence [17]. Here, PIK3CA is linked to prostate cancer.